Acute Chest Syndrome Clinical Trial
Official title:
ST Elevation (Acute Coronary Syndrome Versus Pericarditis;Could Measurement of Lp-associated PLA2 -a Vascular Specific Marker of Inflammation- be Helpful to the Clinician?
Verified date | June 2011 |
Source | Wolfson Medical Center |
Contact | n/a |
Is FDA regulated | No |
Health authority | Israel: Ethics Commission |
Study type | Observational |
A blood test (2-3 cc peripheral venous blood) drawn /used from already available required lab tests to distinguish between pericarditis accompanied with electrocardiogram (ECG) signs mimicking infarction. A test of clinical potential if proven to be able to support either origin of acute chest pain etiology.
Status | Completed |
Enrollment | 40 |
Est. completion date | January 2012 |
Est. primary completion date | November 2011 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Both |
Age group | 18 Years to 70 Years |
Eligibility |
Inclusion Criteria: - acute chest pain - acute ST elevation - elevated troponin I Exclusion Criteria: - patients with recent (> 24 hour chest pain) myocardial infarction - refusing to provide blood samples |
Observational Model: Case Control, Time Perspective: Prospective
Country | Name | City | State |
---|---|---|---|
Israel | The E.Wolfson MC | Holon |
Lead Sponsor | Collaborator |
---|---|
Alexhander Izhaki |
Israel,
Status | Clinical Trial | Phase | |
---|---|---|---|
Withdrawn |
NCT02630394 -
A Pilot Study of Azithromycin Prophylaxis for Acute Chest Syndrome in Sickle Cell Disease
|
Phase 1 | |
Active, not recruiting |
NCT04170348 -
Daily Vitamin D for Sickle-cell Respiratory Complications
|
Phase 2 | |
Recruiting |
NCT03498105 -
Utility of the Cardiac Electrical BiomarkerDisease
|
||
Terminated |
NCT02098993 -
Feasibility Study of Unfractionated Heparin in Acute Chest Syndrome
|
Phase 2 | |
Not yet recruiting |
NCT06214845 -
Early-goal Directed Automated Red Blood Cell Exchange for Acute Chest Syndrome in Sickle Cell Disease
|
N/A | |
Completed |
NCT02187445 -
Inhaled Corticosteroid Use to Prevent Acute Chest Syndrome Recurrence in Children Between 1 and 4 With Sickle Cell Disease: a Feasibility Trial
|
Phase 1 | |
Completed |
NCT01089439 -
Nitric Oxide Therapy for Acute Chest Syndrome in Sickle Cell Disease Children
|
Phase 2 | |
Completed |
NCT03919266 -
Combined Use of a Respiratory Broad Panel Multiplex PCR and Procalcitonin to Reduce Antibiotics Exposure in Hospitalized Sickle-cell Adults With Acute Chest Syndrome.
|
N/A | |
Terminated |
NCT01589926 -
Bi-Level Positive Airway Ventilation for Acute Chest Syndrome
|
N/A | |
Completed |
NCT03250585 -
sPLA2 in EBC During Acute Chest Syndrome
|
||
Completed |
NCT03805581 -
Defibrotide in Sickle Cell Disease-Related Acute Chest Syndrome
|
Phase 2 | |
Recruiting |
NCT03032055 -
Validation of a Predictive Score of Acute Chest Syndrome
|
||
Terminated |
NCT03820466 -
Effect of Platelet Inhibition and / or Lipid Lowering in Non-ACS-patients With Positive Troponin
|
Phase 3 | |
Completed |
NCT00748423 -
Effect of Inhaled Nitric Oxide in Acute Chest Syndrome (INOSTA Study)
|
Phase 2/Phase 3 | |
Completed |
NCT00434473 -
IMPACTS Trial: Investigation of the Modulation of Phospholipase in Acute Chest Syndrome
|
Phase 2 | |
Completed |
NCT02580773 -
Therapeutic Anticoagulation Strategy for Acute Chest Syndrome
|
Phase 3 | |
Completed |
NCT01443728 -
Vitamin D for Sickle-cell Respiratory Complications
|
Phase 2 | |
Recruiting |
NCT05640271 -
Tocilizumab for Acute Chest Syndrome
|
Phase 2 |